Antithrombotic prophylaxis for women in pregnancy, childbirth and the postpartum period

Czech version

Authors: E. Drbohlavová ^1A; J. Gumulec ^2A; A. Buliková ^3A; P. Ďulíček ^4A; J. Hirmerová ^5AB; R. Malý ^6AB; J. Václavík ^7C; P. Kessler ^8D; M. Kacerovský ^9E; M. Macek ^10F; P. Calda ^11F
Authors‘ workplace: Oddělení klinické hematologie Krajské nemocnice Liberec a. s. ¹; Klinika hematoonkologie LF OU a FN Ostrava ²; Oddělení klinické hematologie, LF MU a FN Brno ³; IV. interní hematologická klinika FN Hradec Králové ⁴; II. interní klinika LF UK a FN Plzeň ⁵; I. interní kardioangiologická klinika FN Hradec Králové ⁶; Interní a kardiologická klinika FN Ostrava ⁷; Oddělení hematologie a transfuziologie, Nemocnice Pelhřimov ⁸; Perinatologické centrum intenzivní péče Krajské zdravotní – Nemocnice Most ⁹; Ústav biologie a lékařské genetiky, 2. LF UK a FN Motol ¹⁰; Klinika gynekologie, porodnictví a neonatologie 1. LF UK a VFN v Praze ¹¹; Česká společnost pro trombózu a hemostázu ČLS JEP ^A; Česká angiologická společnost ČLS JEP ^B; Česká internistická společnost ČLS JEP ^C; Česká hematologická společnost ČLS JEP ^D; Česká gynekologická a porodnická společnost ČLS JEP ^E; Společnost lékařské genetiky a genomiky ČLS JEP ^F
Published in: Transfuze Hematol. dnes,31, 2025, No. 3, p. 199-204.
Category: Best Practices
doi: https://doi.org/10.48095/cctahd2025prolekare.cz14

Overview

An interdisciplinary opinion of six professional societies summarizes the rules of antithrombotic prophylaxis in women during pregnancy, childbirth and the puerperium. This is the period when women are at risk of thromboembolic disease, which significantly affects maternal mortality and morbidity. The text follows earlier published recommendations (M. Penka, T. Binder, P. Dulíček. Antithrombotic measures of pregnant women according to the risk of thromboembolic disease (TEN) –⁠ recommended guideline. Ceska Gynekol 2013; 78 (Suppl): 34–36 and the consensus statement of the Sections of the CGSC of the Czech Medical Association of J. E. Purkyně Antithrombotic management of women during pregnancy, delivery and pospartum: part B –⁠ inpatient care. Collection of recommended practices 3/2022) and is supplemented with recent information based on established international recommendations. The aim of the recommendations is to standardise and coordinate care by all professionals involved. For clarity, the text is divided into short paragraphs, tables and graphs.

Keywords:

thrombophilia – Venous thromboembolism – risk factors – antithrombotic drugs

Sources

1. Gumulec J, Dulíček P, Buliková A et al. Doporučený postup stratifikace rizika trombózy a cílené tromboprofylaxe u žen podstupujících asistovanou reprodukci. Transfuze Hematol dnes 2023; 29 (1): 51–59. doi: 10.48095/cctahd2023prolekare.cz1.

2. Middeldorp S, Ganzevoort W. How I treat venous thromboembolism in pregnancy. Blood 2020; 136 (19): 2133–2142. doi: 10.1182/blood. 2019000963.

3. Lamont MC, McDermott C, Thomson AJ, Greer IA. United Kingdom recommendations for obstetric venous thromboembolism prophylaxis: Evidence and rationale. Semin Perinatol 2019; 43 (4): 222–228. doi: 10.1053/j.semperi.2019.03.008.

4. Middeldorp S, Naue C, Köhler C. Thrombophilia, thrombosis and thromboprophylaxis in pregnancy: for what and in whom? Hamostaseologie 2022; 42 (1): 54–64. doi: 10.1055/a-1717-7663

5. Quenby S, Booth K, Hiller L et al. Heparin for women with recurrent miscarriage and inherited thrombophilia (ALIFE2): an international open-label, randomised controlled trial. Lancet 2023; 402 (10395): 54–61. doi: 10.1016/s0140-6736 (23) 00693-1.

6. Ortel TL, Neumann I, Ageno W et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19): 4693–4738. doi: 10.1182/bloodadvances.2020001830.

7. Bates SM, Rajasekhar A, Middeldorp S et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. Blood Adv 2018; 2 (22): 3317–3359. doi: 10.1182/bloodadvances.2018024802.

8. Kearon C, Akl EA, Comerota AJ et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S–e494S. doi: 10.1378/chest.11-2301.

9. Galambosi P, Hiilesmaa V, Ulander VM et al. Prolonged low-molecular-weight heparin use during pregnancy and subsequent bone mineral density. Thromb Res 2016; 143 : 122–126. doi: 10.1016/j.thromres.2016.05.016.

10. Cohen H, Arachchillage DR, Middeldorp S, Beyer-Westendorf J, Abdul-Kadir R. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH. J Thromb Haemost 2016; 14 (8): 1673–1676. doi: 10.1111/jth.13366.

11. Wiegers HMG, Knijp J, van Es N et al. Risk of recurrence in women with venous thromboembolism related to estrogen-containing contraceptives: Systematic review and meta-analysis. J Thromb Haemost 2022; 20 (5): 1158–1165. doi: 10.1111/jth.15661.

12. Lussana F, Coppens M, Cattaneo M, Middeldorp S. Pregnancy-related venous thromboembolism: risk and the effect of thromboprophylaxis. Thromb Res 2012; 129 (6): 673–680. doi: 10.1016/j.thromres.2012.01.017.

13. Tektonidou MG, Andreoli L, Limper M et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78 (10): 1296–1304. doi: 10.1136/annrheumdis-2019-215213.

14. Rolnik DL, Wright D, Poon LCY et al. ASPRE trial: performance of screening for preterm pre-eclampsia. Ultrasound Obstet Gynecol 2017; 50 (4): 492–495. doi: 10.1002/uog.18816.

Doručeno do redakce dne: 10. 7. 2025.

Přijato do tisku dne: 14. 7. 2025.

MUDr. Eva Drbohlavová

Oddělení klinické hematologie

Krajské nemocnice Liberec a. s.

Baarova 526 /15

460 01 Liberec

e-mail: eva.drbohlavova@nemlib.cz